We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Donaldson Company, Inc. (DCI - Free Report) has acquired Nivelles, Belgium-based Univercells Technologies from Gamma Biosciences and Univercells SA in an all-cash deal of €136 million ($147.7 million). Univercells provides biomanufacturing solutions for cell and gene therapy research, development and commercial production.
The acquisition expands Donaldson’s growing offering in the life sciences industry. Also, Univercells’ engineered systems align with Donaldson’s preceding life sciences buyouts as well as the company’s increasing range of organic products.
Univercells will be added to Donaldson’s Life Sciences segment. The buyout is subject to regulatory approvals and customary closing conditions.
Acquisitions have been Donaldson's preferred mode of business expansion to date. The company acquired Durham, NC-based early-stage biotechnology company Isolere Bio in February this year. The Isolere buyout enables Donaldson to create leading separation and filtration solutions for emerging genetic-based drugs. Donaldson’s filtration excellence, together with Isolere’s affinity-phase separation technology, provides end-to-end solutions to the life sciences industry.
IR delivered a trailing four-quarter earnings surprise of 12.6%, on average. In the past 60 days, estimates for Ingersoll Rand’s 2023 earnings have increased 6.7%. The stock has improved 23.3% in the year-to-date period.
Alamo Group Inc. (ALG - Free Report) currently flaunts a Zacks Rank of 1. ALG delivered a trailing four-quarter earnings surprise of 17.7%, on average.
In the past 60 days, estimates for Alamo’s 2023 earnings have increased 12.7%. The stock has gained 28.9% in the year-to-date period.
Axon Enterprise (AXON - Free Report) sports a Zacks Rank of 1 at present. The company has a trailing four-quarter earnings surprise of 44.4%, on average.
In the past 60 days, estimates for Axon’s 2023 earnings have increased 13%. The stock has rallied 18.1% in the year-to-date period.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Donaldson (DCI) Buys Belgium-Based Univercells Technologies
Donaldson Company, Inc. (DCI - Free Report) has acquired Nivelles, Belgium-based Univercells Technologies from Gamma Biosciences and Univercells SA in an all-cash deal of €136 million ($147.7 million). Univercells provides biomanufacturing solutions for cell and gene therapy research, development and commercial production.
The acquisition expands Donaldson’s growing offering in the life sciences industry. Also, Univercells’ engineered systems align with Donaldson’s preceding life sciences buyouts as well as the company’s increasing range of organic products.
Univercells will be added to Donaldson’s Life Sciences segment. The buyout is subject to regulatory approvals and customary closing conditions.
Acquisitions have been Donaldson's preferred mode of business expansion to date. The company acquired Durham, NC-based early-stage biotechnology company Isolere Bio in February this year. The Isolere buyout enables Donaldson to create leading separation and filtration solutions for emerging genetic-based drugs. Donaldson’s filtration excellence, together with Isolere’s affinity-phase separation technology, provides end-to-end solutions to the life sciences industry.
Donaldson Company, Inc. Price
Donaldson Company, Inc. price | Donaldson Company, Inc. Quote
Donaldson's buyout of Purilogics, LLC (June 2022) strengthened its life sciences portfolio by leveraging Purilogics’ unique product offerings.
Zacks Rank & Stocks to Consider
DCI currently carries Zacks Rank #3 (Hold). Some better-ranked companies from the Industrial Products sector are discussed below:
Ingersoll Rand Inc. (IR - Free Report) presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks.
IR delivered a trailing four-quarter earnings surprise of 12.6%, on average. In the past 60 days, estimates for Ingersoll Rand’s 2023 earnings have increased 6.7%. The stock has improved 23.3% in the year-to-date period.
Alamo Group Inc. (ALG - Free Report) currently flaunts a Zacks Rank of 1. ALG delivered a trailing four-quarter earnings surprise of 17.7%, on average.
In the past 60 days, estimates for Alamo’s 2023 earnings have increased 12.7%. The stock has gained 28.9% in the year-to-date period.
Axon Enterprise (AXON - Free Report) sports a Zacks Rank of 1 at present. The company has a trailing four-quarter earnings surprise of 44.4%, on average.
In the past 60 days, estimates for Axon’s 2023 earnings have increased 13%. The stock has rallied 18.1% in the year-to-date period.